New Visiongain report says that the Global Electrosurgical Energy Devices Market Set To Grow To $4.9bn By 2023

30 July 2018
Pharma

Visiongain’ has launched a new pharma report Global Electrosurgical Energy Devices Market Forecast 2018-2028: Electrosurgical Generators, Instruments and Accessories, Argon and Smoke Management Systems, Bipolar Instruments, Monopolar Instruments, Patient Return Electrodes, Dispersive Electrodes, Cords, Cables and Adapters, General Surgery, Gynaecologic, Urologic, Orthopaedic, Cardiovascular, Cosmetic, Neurosurgery

The electrosurgical energy devices market is driven by factors such as increasing geriatric population, increasing demand for minimally invasive surgeries, and the launch of technologically advanced electrosurgical energy devices. However, pitfalls such as stringent government regulations are restraining the market for electrosurgical energy devices.
By product type, electrosurgical instruments and accessories dominated the market in 2017 owing to the high use of instruments and accessories in different surgical procedures such as cosmetic surgery, neurosurgery, cardiovascular surgery, urologic surgery, general surgery and others.

The lead analyst of the report commented “The growth of the electrosurgical device market is estimated to be catalysed by opportunities in untapped, emerging markets with high potential due to improving healthcare infrastructure, unmet healthcare needs, rise in chronic diseases and increased demands for minimally invasive surgeries.

The healthcare industry in emerging economies is developing at a significant rate due to augmentation in demand for better healthcare services, significant investments to improve healthcare infrastructure and growth of medical tourism industry in emerging countries.”

Leading companies featured in the report include B. Braun Melsungen AG, Bovie Medical Corporation, Conmed, ERBE Elektromedizin GmbH , Johnson & Johnson, KLS Martin Group, Medtronic, Megadyne Medical Products, Inc., Olympus Corporation, Utah Medical Products, Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever